{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":" Cardiorenal Outcomes with Tirzepatide Compared with Dulaglutide in Patients with Diabetes and CVD","description":" Is tirzepatide associated with a broader reduction in cardiorenal adverse outcomes compared with dulaglutide in patients with type 2 diabetes and cardiovascular disease (CVD? The SURPASS-CVOT, the first cardiovascular outcomes trial using an active incretin-based comparator, previously demonstrated that tirzepatide was noninferior to dulaglutide for major adverse cardiovascular events, including CV death, myocardial infarction, and stroke. A current analysis expands these findings by examining a wider spectrum of adverse events to further characterize the comparative cardiorenal effects of tirzepatide.    In this interview, Matthew Martinez, MD, FACC and\u202fSteven E. Nissen, MD, MACC examine the SURPASS-CVOT Randomized Clinical Trial.  ","author_name":"ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research","author_url":"http:\/\/accelaccorg.libsyn.com\/website","html":"